Immunosuppressive Agents
13
1
1
3
Key Insights
Highlights
Success Rate
50% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 90/100
23.1%
3 terminated out of 13 trials
50.0%
-36.5% vs benchmark
23%
3 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (13)
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
Model Informed preciSion doSIng tO iNdividualise and Optimize Pharmacotherapeutic Treatment
Eduction in ImmunoSuppressive Regimen Among Kidney Transplant Recipients Patients Admitted to the Intensive Care Unit for Septic Shock and/or Acute Respiratory Failure
Impact of SCFA Supplementation on Gut Microbiome Composition of Kidney Transplant Recipients
Impact of SCFA Supplementation on Metabolic Profiles in Serum and Urine of Kidney Transplant Recipients.
Natural Killer Cell (CYNK-001) Infusions in Adults with AML
Immunosuppressants to Postoperative Infection and Death
Precision Drug Use of Immunosuppressants Guided by Population Pharmacokinetics/Pharmacodynamic Models in Kidney Transplant Patients
Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM
Anti-HLA Immunization And Immunosuppressive Therapy Management In Kidney Transplant Patients Returning to Dialysis
Effect of Steroids During Pneumocystis Infection Among Non HIV Immunocompromised Patients
An Open, Single Centre, Randomised, Parallel Group Study to Investigate Three Different Immunosuppressive Regimens
MMF and Calcineurin Inhibitor Withdrawal in CAN